Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed
Adial to focus on late-stage clinical development for AD04 for alcohol use disorder; potential sale of Purnovate to new company...
Adial to focus on late-stage clinical development for AD04 for alcohol use disorder; potential sale of Purnovate to new company...
BASKING RIDGE, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as...
PURCHASE, NY, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care,...
Exclusive list recognizes most exciting and innovative health startups in the New York regionNEW YORK, Feb. 01, 2023 (GLOBE NEWSWIRE)...
Glen Rock, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a...
Bagsværd, Denmark, 1 February 2023 – Novo Nordisk A/S has filed its Annual Report 2022 on Form 20-F for the...
WARSAW, Ind., Feb. 01, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively...
FDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study New Publication Supports Eventual Pursuit of AG200-15 Extended Regimen Development...
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging...
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science...
REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology...